drugset / Trial / NCT06226506

Comparative Pharmacokinetic Study of Aprepitant Injection in Humans

NCT06226506

Phase 1 Unknown 24 enrolled The Affiliated Hospital of Qingdao University
RandomizedCrossoverOpen-labelTreatment

Summary

This is a single-center, open, randomized, single-dose, two-cycle, two-sequence, crossover pharmacokinetic study in healthy adult subjects. The trial is planned to enroll 24 healthy subjects. Subjects will be randomized to one of two groups (Group A: T-R, Group B: R-T) according to the randomization table. The washout period (dosing interval) between doses will be at least 7 days. For example, for a washout period of 7 days, all subjects will receive the appropriate drug according to the randomized schedule on Day 1 of Cycle 1 and Day 8 of Cycle 2 of the trial.

Timeline

Start
2024-01-23
Primary completion
2024-01-25
Completion
2025-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 32 mg

Indications

No indication recorded.